A5041614892- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Gallbladder and Bile Duct Disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Intraperitoneal and Appendiceal Malignancies
- Colorectal Cancer Screening and Detection
- Gastrointestinal disorders and treatments
- Appendicitis Diagnosis and Management
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Pediatric Hepatobiliary Diseases and Treatments
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
- Esophageal and GI Pathology
- Economic and Financial Impacts of Cancer
- Lung Cancer Research Studies
- Colorectal Cancer Surgical Treatments
- CAR-T cell therapy research
- Immune Cell Function and Interaction
University of Pittsburgh Medical Center
2020-2025
University of Florida
2022-2024
University of Pittsburgh
2020-2024
Yahoo (United Kingdom)
2024
Memorial Sloan Kettering Cancer Center
2022
Massachusetts General Hospital
2022
Johns Hopkins University
2022
Rutgers, The State University of New Jersey
2022
Rutgers Cancer Institute of New Jersey
2022
Huzhou University
2022
T cell immunoglobulin and ITIM domain (TIGIT) CD226 emerge as a novel cosignaling pathway in which TIGIT serve costimulatory coinhibitory receptors, respectively, for the ligands CD155 CD112. In this study, we describe CD112R, member of poliovirus receptor–like proteins, new receptor human cells. CD112R is preferentially expressed on cells inhibits receptor–mediated signals. We further identify that CD112, widely antigen-presenting tumor cells, ligand with high affinity. competes to bind...
Objective Recent studies have found aristaless-related homeobox gene (ARX)/pancreatic and duodenal 1 (PDX1), alpha-thalassemia/mental retardation X-linked (ATRX)/death domain-associated protein (DAXX) alternative lengthening of telomeres (ALT) to be promising prognostic biomarkers for non-functional pancreatic neuroendocrine tumours (NF-PanNETs). However, they not been comprehensively evaluated, especially among small NF-PanNETs (≤2.0 cm). Moreover, their status in (NETs) from other sites...
Background & AimsNext-generation sequencing (NGS) of pancreatic cyst fluid is a useful adjunct in the assessment patients with cyst. However, previous studies have been retrospective or single institutional experiences. The aim this study was to prospectively evaluate NGS on multi-institutional cohort real time.MethodsThe performance 22-gene panel (PancreaSeq) first retrospectively confirmed and then within 2-year timeframe, PancreaSeq testing used endoscopic ultrasound–guided fine-needle...
PURPOSE Previous studies suggest that besides anatomy (A: resectable, borderline resectable [BR], or locally advanced [LA]) also biologic (B: carbohydrate antigen 19-9 [CA 19-9]) and conditional (C: performance status) factors should be considered when staging patients with localized pancreatic ductal adenocarcinoma (PDAC). The prognostic value of the combined ABC has not been quantitatively validated. METHODS In this retrospective cohort study, we evaluated PDAC treated initial (modified)...
To our knowledge, this study reports on the largest cohort of long-term survivors (LTSs) (≥10 years) following a diagnosis pancreatic ductal adenocarcinoma (PADC) and identifies characteristics associated with LTS.To determine patient, tumor, surgical, sociodemographic LTS.A nationwide retrospective patients invasive PADC (International Classification Diseases for Oncology, Third Edition codes 8140/3, 8500/3, 8021/3, 8035/3) was conducted using data collected in National Cancer Database...
Robotic pancreatectomy is gaining momentum; however, limited data exist on the long-term survival of this approach for pancreatic ductal adenocarcinoma (PDAC). The objective study to compare oncologic outcomes robotic pancreaticoduodenectomy (RPD) and distal (RDP) open surgery in patients with PDAC.Robotic stages I-III PDAC were obtained from 2010 2016 National Cancer Database.We identified 17 831 pancreaticoduodenectomies 2718 pancreatectomies which 626 (4%) 332 (12%) robotic, respectively....
Abstract Background Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to provide realistic estimates oncologic outcomes in these patients. Methods international retrospective cohort included all consecutive presenting PDAC at least 1 cycle (m)FOLFIRINOX 5 referral centers from the United States Netherlands...
We report the development and validation of a combined DNA/RNA next-generation sequencing (NGS) platform to improve evaluation pancreatic cysts.
5-Fluorouracile, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) has not been extensively used in the neoadjuvant setting because of concerns with safety toxicity. We evaluated our institutional experience FOLFIRINOX borderline resectable pancreatic adenocarcinoma (BRPAC). The primary endpoints were completion therapy to surgery negative resection margin (R0) rate. Patients BRPAC treated retrospectively analyzed. Between August 2011 September 2013, 20 patients identified. Most (88.8%)...
The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, or without dose modifications [(m)FOLFIRINOX], for patients borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is uncertain.
Objective: To compare the rate of postoperative 30-day complications between laparoscopic pancreaticoduodenectomy (LPD) and robotic (RPD). Background: Previous studies suggest that minimally invasive (MI-PD)—either LPD or RPD—is noninferior to open in terms operative outcomes. However, a direct comparison two approaches has not been rigorously performed. Methods: Patients who underwent MI-PD were abstracted from 2014 2019 pancreas-targeted American College Surgeons National Sample Quality...
Neoadjuvant therapy (NAT) is rarely associated with a complete histopathologic response in patients pancreatic ductal adenocarcinoma (PDAC) but results downstaging of regional nodal disease. Such after NAT may have implications for the use additional adjuvant (AT).
Abstract Background Which patients with locally advanced pancreatic cancer may benefit from surgical exploration after induction treatment remains debated. The aim of this retrospective cohort study was to identify independent factors for overall survival cancer, which are available at restaging therapy. Methods Consecutive the Trans-Atlantic Pancreatic Surgery who underwent FOLFIRINOX as chemotherapy were included. Multivariable Cox proportional hazards analyses contour plots used predicted...